Intracerebroventricular administration of GM1 ganglioside topresenile Alzheimer patients
L.E. Augustinsson
Bok Engelsk 1997
| Utgitt | 1997
|
|---|---|
| Omfang | Side 26- 33
|
| Opplysninger | We have conducted a preliminary study of the optimum conditions for atherapeutic effect of ganglioside GM1 in Alzheimer's disease. Fivepatients with the early onset form of Alzheimer's disease (AD type I)received the ganglioside by intracerebroventricular administrationfor 12 months. Bilateral stereotactic punction of the frontal hornsof the ventricular system was performed, and shunt catheters wereimplanted and connected to a programmable pump. The optimum GM1 dosevaried between 20 and 30 mg/24 h. Neurological, neuropsychological,psychiatric and neurochemical examinations were performed 7 daysbefore surgery and on days 30, 90, 180 and 360. No patient found thesurgery difficult and no patient or relative regretted that theyparticipated in the study. The patients became more active and saferin relation to others and to performance of various activities fromday 90. The cerebrospinal fluid level of the monoamine metaboliteshomovanillic acid and 5-hydroxyindoleacetic acid and the neuropeptidesomatostatin increased.
|
| Emner |
